WuXi Biologics (Cayman) (FRA:1FW2) Short-Term Debt & Capital Lease Obligation : €94 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. WuXi Biologics (Cayman)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €94 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. WuXi Biologics (Cayman)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €492 Mil.

WuXi Biologics (Cayman) Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Short-Term Debt & Capital Lease Obligation Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

68.34

104.06

309.22

199.11

93.92

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial													309.22	349.48	199.11	165.04	93.92

WuXi Biologics (Cayman) Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

WuXi Biologics (Cayman) Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines